FDA AdCom overwhelmingly supports accelerated approval for Biogen’s tofersen in ALS
AdCom panelists backed an accelerated approval for Biogen’s tofersen in a rare form of ALS based on a new surrogate biomarker.

AdCom panelists backed an accelerated approval for Biogen’s tofersen in a rare form of ALS based on a new surrogate biomarker.
The collaboration will deliver data-driven predictive analytics, AI and ML capabilities for customers.
The global pharmaceutical industry experienced a 10% rise in new job postings related to social responsibility in Q3 2022 compared…
Cloudbyz launches new electronic data capture platform for clinical trials
Atea Pharmaceuticals announces results of bemnifosbuvir for Covid-19
Clario launches comprehensive clinical trial solution
BWH’s investigators test Foralumab in pilot trial for Covid-19